Product: TSG101 Antibody
Catalog: DF8427
Description: Rabbit polyclonal antibody to TSG101
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 45 kDa; 44kD(Calculated).
Uniprot: Q99816
RRID: AB_2841675

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Bovine(91%), Horse(100%), Sheep(91%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
TSG101 Antibody detects endogenous levels of total TSG101.
RRID:
AB_2841675
Cite Format: Affinity Biosciences Cat# DF8427, RRID:AB_2841675.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ESCRT I complex subunit TSG101; ESCRT-I complex subunit TSG101; TS101_HUMAN; TSG 10; TSG 101; TSG10; Tsg101; Tumor susceptibility gene 10; Tumor susceptibility gene 101; Tumor susceptibility gene 101 protein; Tumor susceptibility protein; Tumor susceptibility protein isoform 3; VPS 23; VPS23;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
Q99816 TS101_HUMAN:

Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas.

Sequence:
MAVSESQLKKMVSKYKYRDLTVRETVNVITLYKDLKPVLDSYVFNDGSSRELMNLTGTIPVPYRGNTYNIPICLWLLDTYPYNPPICFVKPTSSMTIKTGKHVDANGKIYLPYLHEWKHPQSDLLGLIQVMIVVFGDEPPVFSRPISASYPPYQATGPPNTSYMPGMPGGISPYPSGYPPNPSGYPGCPYPPGGPYPATTSSQYPSQPPVTTVGPSRDGTISEDTIRASLISAVSDKLRWRMKEEMDRAQAELNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELSSALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIEDTIFYLGEALRRGVIDLDVFLKHVRLLSRKQFQLRALMQKARKTAGLSDLY

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Dog
100
Rabbit
100
Bovine
91
Sheep
91
Pig
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q99816 As Substrate

Site PTM Type Enzyme
A2 Acetylation
S6 Phosphorylation
K14 Acetylation
Y15 Phosphorylation
K16 Acetylation
Y32 Phosphorylation
S48 Phosphorylation
T56 Phosphorylation
Y63 Phosphorylation
K90 Acetylation
K101 Ubiquitination
T220 Phosphorylation
S222 Phosphorylation
T225 Phosphorylation
K237 Acetylation
K237 Ubiquitination
K257 Ubiquitination
K269 Ubiquitination
K286 Ubiquitination
K292 Ubiquitination
K293 Ubiquitination
S299 Phosphorylation
S300 Phosphorylation
K304 Ubiquitination
S309 Phosphorylation
K361 Ubiquitination
K379 Ubiquitination
Y390 Phosphorylation

Research Backgrounds

Function:

Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. Required for the exosomal release of SDCBP, CD63 and syndecan. It may also play a role in the extracellular release of microvesicles that differ from the exosomes.

PTMs:

Monoubiquitinated at multiple sites by LRSAM1 and by MGRN1. Ubiquitination inactivates it, possibly by regulating its shuttling between an active membrane-bound protein and an inactive soluble form. Ubiquitination by MGRN1 requires the presence of UBE2D1.

Subcellular Location:

Cytoplasm. Early endosome membrane>Peripheral membrane protein>Cytoplasmic side. Late endosome membrane>Peripheral membrane protein. Cytoplasm>Cytoskeleton>Microtubule organizing center>Centrosome. Midbody>Midbody ring. Nucleus.
Note: Mainly cytoplasmic. Membrane-associated when active and soluble when inactive. Nuclear localization is cell cycle-dependent. Interaction with CEP55 is required for localization to the midbody during cytokinesis.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas.

Subunit Structure:

Component of the ESCRT-I complex (endosomal sorting complex required for transport I) which consists of TSG101, VPS28, a VPS37 protein (VPS37A to -D) and MVB12A or MVB12B in a 1:1:1:1 stoichiometry. Interacts with VPS37A, VPS37B and VPS37C. Interacts with DMAP1. Interacts with ubiquitin. Interacts with stathmin, GMCL and AATF (By similarity). Component of an ESCRT-I complex (endosomal sorting complex required for transport I) which consists of TSG101, VPS28, VPS37A and UBAP1 in a 1:1:1:1 stoichiometry. Interacts with HGS; the interaction mediates the association with the ESCRT-0 complex. Interacts with GGA1 and GGA3. Interacts (via UEV domain) with PDCD6IP/AIP1. Interacts with VPS28, SNF8 and VPS36. Self-associates. Interacts with MVB12A; the association appears to be mediated by the TSG101-VPS37 binary subcomplex. Interacts with VPS37D. Interacts with LRSAM1. Interacts with CEP55; the interaction is required for cytokinesis but not for viral budding. Interacts with PDCD6. Interacts with LITAF. Interacts with MGRN1. Interacts with ARRDC1; recruits TSG101 to the plasma membrane.

(Microbial infection) Interacts with HIV-1 p6.

(Microbial infection) Interacts with human spumavirus Gag.

(Microbial infection) Interacts with HTLV-1 Gag.

(Microbial infection) Interacts with Ebola virus VP40.

(Microbial infection) Interacts with EIAV p9; the interaction has been shown in vitro.

(Microbial infection) Interacts with Lassa virus protein Z.

(Microbial infection) Interacts with hepatitis E virus protein ORF3.

Family&Domains:

The UEV domain is required for the interaction of the complex with ubiquitin. It also mediates the interaction with PTAP/PSAP motifs of HIV-1 P6 protein and human spumaretrovirus Gag protein.

The coiled coil domain may interact with stathmin.

The UEV domain binds ubiquitin and P-[ST]-A-P peptide motif independently.

Belongs to the ubiquitin-conjugating enzyme family. UEV subfamily.

Research Fields

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

References

1). Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis. International Journal of Nanomedicine (PubMed: 35959282) [IF=8.0]

Application: WB    Species: Mouse    Sample: BM-MSCs cells

Figure 1 Characterization of exosomes: the size distributions of blank exosome (A) and exosome-doxorubicin (B) measured by NTA. The mean particle diameters were 141.6 nm for free exosome and 178.1 nm for exosome-doxorubicin. The morphology of blank exosome (C) and exosome-doxorubicin (D) as observed by TEM. (E) Western blotting analysis of the exosomal proteins CD81 and TSG101.

2). Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway. Apoptosis (PubMed: 37060507) [IF=7.2]

3). Discovery and validation of extracellular vesicle‐associated miRNAs as noninvasive detection biomarkers for early‐stage non‐small‐cell lung cancer. Molecular Oncology (PubMed: 33340250) [IF=6.6]

Application: WB    Species: Human    Sample: lung tissues

Figure 1. Characterisation of EVs derived from the serum and plasma of NSCLC patients and controls. (a) The shape and structure of serum and plasma EVs isolated by EXOquick kit under TEM. The red arrow represents EVs with typical characteristics (scale bars are 200 nm). (b) The size of EVs derived from control groups and NSCLC groups was analysed by NTA. (c) Western blots of EVs membrane markers, including Alix, CD63, TSG101, CD9, and one negative marker ALB.

4). Exosomes derived from smooth muscle cells ameliorate diabetes‐induced erectile dysfunction by inhibiting fibrosis and modulating the NO/cGMP pathway. Journal of Cellular and Molecular Medicine (PubMed: 33009701) [IF=5.3]

Application: WB    Species: Rat    Sample: CCSMCs

FIGURE 1Cell identification and exosome characterization. (A) Representative flow cytometry histograms of BMSCs and ADSCs show positive staining for CD29 and CD90 but not for CD34 and CD45. (B) BMSCs and ADSCs were successfully induced into osteoblasts (positively stained with Alizarin Red S) and adipocytes (positively stained with Oil Red O). The magnification is 100×. (C) Representative immunofluorescence results of CCSMCs show positive expression for α-SMA and desmin. Scale bars = 50 μm. (D) Exosomes derived from CCSMCs, BMSCs and ADSCs were observed using transmission electron microscopy, and the particle size distributions of the exosomes were measured by nanoparticle tracking analysis. Scale bars = 100 nm. (E) Representative results of Western blot analysis of exosomes derived from CCSMCs, BMSCs and ADSCs show positive expression for CD9, CD63 and TSG101 but not for calnexin. CCSMC: corpus cavernosum smooth muscle cell; BMSC: bone marrow stem cell; ADSC: adipose-derived stem cell; CCSMC-EXOs: exosomes derived from corpus cavernosum smooth muscle cells; BMSC-EXOs: exosomes derived from bone marrow stem cells; ADSC-EXOs: exosomes derived from adipose-derived stem cells; α-SMA: α-smooth muscle actin; DAPI: 4’,6-diamidino-2-phenylindole

5). Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy. Cancers (PubMed: 35884614) [IF=5.2]

6). Expression level and diagnostic value of exosomal NEAT1/miR‐204/MMP‐9 in acute ST‐segment elevation myocardial infarction. IUBMB Life (PubMed: 32916037) [IF=4.6]

Application: WB    Species: human    Sample: serum exosomes

FIGURE 2 |Exosome identification. (a) Structure of exosomes under TEM, magnification 150,000×. (b) Western blot showed the expression of exosome markers CD63 and TSG101

7). Human umbilical cord mesenchymal stem cell-derived exosomes promote neurological function recovery in rat after traumatic brain injury by inhibiting the activation of microglia and astrocyte. Regenerative Therapy (PubMed: 36092501) [IF=4.3]

8). Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide. Oncology Reports (PubMed: 33649836) [IF=4.2]

Application: WB    Species: Human    Sample: U251s and U251r cells

Figure 2. Isolation and identification of exosomes from U251s and U251r cells. (A) Exosomes were isolated from U251s or U251r cells by differential velocity centrifugation, and representative images of sExo and rExo were captured under a transmission electron microscope. Scale bar, 200 nm. (B) sExo and rExo diameters were measured using the Zetasizer Nano ZS90 particle size analyzer. The size distribution of the vesicles was concentrated in the range of 40–120 nm. (C) Western blotting was used to examine the expression of exosomal markers CD63 and TSG101 in U251s cells, sExo and rExo; GAPDH was used as an endogenous reference. (D and E) Quantitative analysis of the protein expression level of CD63 and TSG101. **P<0.01, ***P<0.001. U251r, temozolomide-resistant U251 glioma cells; U251s, temozolomide-sensitive U251 glioma cells; sExo, exosomes of U251s cells; rExo, exosomes of U251r cells.

9). Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma. World Journal of Surgical Oncology (PubMed: 36471393) [IF=3.2]

Application: WB    Species: Human    Sample: HepG2 cells

Fig. 2 sEV characterization and verification. A Representative electron microscopy image of plasma sEVs. Scale bar: 200 nm. B The size and concentration distribution of the sEVs in plasma detected using NTA. The particle size distribution of sEVs mainly ranged from 17.5 to 300 nm and peaked at 147.5 nm. C The protein expression of three positive markers and one negative marker of sEVs was detected in the sEVs-NC, sEVs-HCC, and cell lysate groups. The protein samples from sEVs extracted from the plasma of control patients and patients with HCC were labeled “sEVs-NC” and “sEVs-HCC,” respectively. The protein sample of the “Cell Lysate” group was extracted from HepG2 cells without any treatment. All samples were normalized by determining the concentration using the BCA assa

10). Pancreatic Cancer-Derived Exosomes Promote the Proliferation, Invasion, and Metastasis of Pancreatic Cancer by the miR-3960/TFAP2A Axis. Journal of Oncology (PubMed: 36284637)

Application: WB    Species: Mice    Sample:

Figure 2 The identification of PANC-1-derived exosomes. (x¯¯±s, n =3). (a) Transmission electron microscopy. (Scale bar =200 nm) (b and c) Nanoparticle Tracking analysis. (d) The average levels of TSG101, Alix, CD81, CD9, CD63, HSP70 and C-myc. ∗∗P <0.01 compared to the cell group.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.